Bellesi G, Alterini R, Messori A, Bosi A, Bernardi F, di Lollo S, Ferrini P R
Cattedra e Divisione di Ematologia, Università degli Studi e Ospedale di Careggi, Firenze, Italy.
Br J Cancer. 1989 Aug;60(2):244-8. doi: 10.1038/bjc.1989.262.
Fifty-five consecutive patients with primary gastrointestinal intermediate or high grade non-Hodgkin's lymphoma were analysed to assess the efficacy of chemotherapy following surgical tumour resection. Histological subtypes were high grade (n = 18), intermediate grade (n = 36) and unclassified (n = 1). The majority of patients had gastric presentation (71%) and localised disease (84%). Surgery consisted of radical resection in 25 patients (45%) and partial or palliative excision in the remaining cases (22 and 8 respectively). Four subjects died within 3 months of surgery, two patients refused adjuvant chemotherapy and 49 completed the postoperative chemotherapeutic programme. Chemotherapy included either Fi2/74 (adriamycin + vincristine + bleomycin + cyclophosphamide + prednisone) or Fi3/74 (adriamycin + VM26 + bleomycin + cyclophosphamide + prednisone). Excluding the group who underwent radical tumour resection, postoperative chemotherapy induced complete remission in 81% of the remaining 30 patients. The 10-year cause-specific survival for the 53 treated patients was 76% (median follow-up 58 months) with a stable curve plateau after 80 months. Proportional-hazard multivariate statistics showed that survival was influenced by type of surgical resection (P less than 0.05) and stage (P less than 0.05), whereas age, sex and histological subtype were not influential. Our data indicate that chemotherapy following surgical resection of gastrointestinal lesion induces long-term remission in primary gastrointestinal lymphomas.
对55例连续性原发性胃肠道中、高度非霍奇金淋巴瘤患者进行分析,以评估手术切除肿瘤后化疗的疗效。组织学亚型为高度(n = 18)、中度(n = 36)和未分类(n = 1)。大多数患者表现为胃部病变(71%)且疾病局限(84%)。手术方式包括25例患者(45%)行根治性切除,其余病例分别行部分切除或姑息性切除(分别为22例和8例)。4例患者在术后3个月内死亡,2例患者拒绝辅助化疗,49例患者完成了术后化疗方案。化疗方案包括Fi2/74(阿霉素+长春新碱+博来霉素+环磷酰胺+泼尼松)或Fi3/74(阿霉素+VM26+博来霉素+环磷酰胺+泼尼松)。排除行根治性肿瘤切除的患者组,术后化疗使其余30例患者中的81%达到完全缓解。53例接受治疗患者的10年病因特异性生存率为76%(中位随访58个月),80个月后生存曲线呈稳定平台期。多因素比例风险统计显示,生存受手术切除类型(P<0.05)和分期(P<0.05)影响,而年龄、性别和组织学亚型无影响。我们的数据表明,胃肠道病变手术切除后化疗可使原发性胃肠道淋巴瘤获得长期缓解。